Report Overview

The US Inflammatory Bowel Disease (IBD) therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 4.7% during the forecast period.

The percentage of people diagnosed with IBD (either Crohns disease or ulcerative colitis) increased from 0.9% of US adults in 1999 to 1.3% of US adults in 2015. This percentage is further expected to expand in the near future; thereby, promising significant growth for the IBD market during the forecast period



Market Growth Drivers

The factors such as the significant prevalence of IBD such as Crohns disease and ulcerative colitis across the country contributing to the market growth. As per the Centers for Disease Control and Prevention (CDC), the prevalence of Crohns disease and ulcerative colitis in the US was 201 and 238 per 100,000 population respectively in 2015. Moreover, the CDC also estimates the incidence rate of types of IBD across the country. As per the CDC, the incidence of Crohns disease and ulcerative colitis were nearly 14.6 and 14.3 per 100,000 population respectively in 2015